Not a good buy right now: price just fell hard (-5.48% regular session) and near-term setup doesn’t show a clean “must-buy-now” edge.
Without Intellectia buy signals and with bearish near-term pattern stats (next week bias), odds favor a better entry later rather than chasing today.
If you must act immediately, it’s more of a speculative rebound attempt than a high-conviction buy; the chart suggests downside risk toward ~$19.10 support before a cleaner bounce.
Trend/price action: Sharp down day (-5.48%) with price at $20.51, sitting slightly below the pivot (20.63) → near-term momentum weakened.
MACD: Histogram positive (0.201) but positively contracting → bullish momentum is fading rather than accelerating.
RSI(6): ~55 (neutral) → not oversold; no “forced bounce” signal yet.
Moving averages: Converging → consolidation/indecision, typically not the strongest timing signal.
Levels: Support S1 ~$19.10 (next key downside magnet), Support S2 ~$18.15; Resistance R1 ~$22.16 (first meaningful reclaim level).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning vs flow: Open interest put/call 0.45 is constructive (more call OI than puts), but today’s put/call volume 2.88 is bearish (traders buying puts / hedging aggressively today).
Volatility: 30D IV ~69.7 vs HV ~58.3 → options are pricing elevated uncertainty.
Activity: Today’s volume vs 30D avg ~8.57x (unusual), suggesting the drop triggered heavy options activity.
Takeaway: Sentiment skewed defensive in the near term despite longer-run call-heavy positioning.
Technical Summary
Sell
4
Buy
7
Positive Catalysts
Possible business tailwind noted by analysts: international nurse business rebound could help margins.
on 2026-02-19 after hours—can reset the narrative if guidance improves.
Neutral/Negative Catalysts
No supportive news flow in the last week to counter the selloff.
Near-term technical damage: big down day with fading MACD momentum; risk of testing ~$19.10 support.
Options tape is bearish today (put volume dominates), consistent with near-term caution.
Next-week statistical bias is negative (-~3.2%), aligning with the weak near-term setup.
Business pressure remains: staffing conditions described as “uneven” near term by analysts.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $634.5M, down -7.71% YoY → top-line still contracting.
Profitability: Net income $29.3M, up +319% YoY; EPS $0.76, up +322% YoY → earnings improved sharply despite revenue decline (suggests cost actions/normalization vs prior period).
Margins: Gross margin 23.17%, down -7.36% YoY → margin pressure remains a key concern even with EPS rebound.
Overall: Mixed quality—earnings up, but the core demand/top-line and gross margin trend are not yet clearly re-accelerating.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent tone: Mixed but slightly constructive—Citizens/JMP maintains Outperform with targets raised earlier (to $24) but later trimmed modestly (to $22); UBS stays Neutral with PT lifted to ~$20.50 (around the current price).
Price targets vs price (~$20.51): Upside to $22–$24 exists (about ~7% to ~17%), but the Street is not uniformly bullish.
Wall Street pros: Belief in gradual demand improvement and longer-term staffing stabilization; international nurse rebound could aid margins.
Wall Street cons: Near-term conditions still uneven and margins pressured; recent target cut (Citizens $24→$22) signals tempered near-term expectations.
Influential trading check: Hedge funds and insiders show neutral activity (no significant recent trend). No recent congress trading data available.
Wall Street analysts forecast AMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMN is 21.5 USD with a low forecast of 20.5 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMN is 21.5 USD with a low forecast of 20.5 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
3 Hold
1 Sell
Moderate Buy
Current: 20.850
Low
20.5
Averages
21.5
High
22
Current: 20.850
Low
20.5
Averages
21.5
High
22
Citizens
Outperform
maintain
$24 -> $22
AI Analysis
2025-12-19
Reason
Citizens
Price Target
$24 -> $22
AI Analysis
2025-12-19
maintain
Outperform
Reason
Citizens lowered the firm's price target on AMN Healthcare to $22 from $24 and keeps an Outperform rating on the shares. The firm's December Staffing Trends report updates provider contract labor spending, JOLTS data, nurse wage and exam trends, and reviews 2025 sector M&A activity, the analyst tells investors in a research note. While near-term conditions may remain uneven, the longer-term outlook for healthcare staffing is constructive, with potential for secular stabilization in 2026, the firm adds.
UBS
Neutral
maintain
$18
2025-11-07
Reason
UBS
Price Target
$18
2025-11-07
maintain
Neutral
Reason
UBS raised the firm's price target on AMN Healthcare to $20.50 from $18 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AMN
